RxDoctor Payments Data

Hakim Morsli, MD

Cardiovascular Disease · Sarasota, FLNPI 1023009909

Payments from drug & device makers

$198,385in general payments, 2019–2025

Across 197 payments — averaging $1007.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$101K
  • Johnson & Johnson$73K
  • AstraZeneca$12K
  • Livanova USA, Inc.$5K
  • Bayer$4K
  • Cvrx, Inc.$357
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$81,79994%
  • Travel & lodging$4841%
  • Food & beverage$4,5865%
  • Education$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,385 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,590,069
Medicare patients
5,124
Services billed
18,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis82$2,102,787
EliquisApixaban997$1,273,772
XareltoRivaroxaban779$1,041,087
EntrestoSacubitril/Valsartan313$412,472
Repatha SureclickEvolocumab142$184,864
FarxigaDapagliflozin Propanediol181$171,739
MultaqDronedarone Hcl62$105,760
JardianceEmpagliflozin54$68,158
BrilintaTicagrelor41$43,152
Praluent PenAlirocumab23$27,117
Repatha PushtronexEvolocumab24$21,008
Repatha SyringeEvolocumab29$20,786
Metoprolol Succinate1,448$18,880
EdarbyclorAzilsartan Med/Chlorthalidone20$13,746
Atorvastatin Calcium1,565$11,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$167$3,376,5601,079 claims
Johnson & JohnsonXarelto$73,155$1,041,087779 claims
NovartisEntresto$101,397$412,472313 claims
AstraZenecaFarxiga, Brilinta$12,489$214,891222 claims
Sanofi-aventis U.S. LLCMultaq$25$105,76062 claims
Boehringer IngelheimJardiance$96$68,15854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →